Entresto vs Leqvio
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Entresto | US Leqvio | |
|---|---|---|
| Generic name | sacubitril/valsartan | inclisiran |
| Drug class | ARNI (Neprilysin Inhibitor + ARB) | siRNA PCSK9-Lowering Therapy |
| Treats | Chronic heart failure | High cholesterol, cardiovascular disease |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | Novartis |
| Year approved | 2015 | 2021 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | $90M |
| Common side effects | Low blood pressure, High potassium, Kidney problems, Dizziness | Injection site reactions, Joint pain, Urinary tract infection, Shortness of breath |
Frequently asked questions
Is Entresto or Leqvio better?
Neither is universally "better." Entresto (sacubitril/valsartan) and Leqvio (inclisiran) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Entresto and Leqvio?
Entresto is a ARNI (Neprilysin Inhibitor + ARB) made by Novartis, while Leqvio is a siRNA PCSK9-Lowering Therapy made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Entresto has the larger estimated TV advertising budget of the two.